TOP > 外国特許検索 > METHOD FOR INHIBITING PROLIFERATION OF HIGH LIX1L-EXPRESSING TUMOR CELL, AND TUMOR CELL PROLIFERATION-INHIBITING PEPTIDE

METHOD FOR INHIBITING PROLIFERATION OF HIGH LIX1L-EXPRESSING TUMOR CELL, AND TUMOR CELL PROLIFERATION-INHIBITING PEPTIDE

外国特許コード F150008327
掲載日 2015年4月22日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2014JP059780
国際公開番号 WO 2014168064
国際出願日 平成26年4月2日(2014.4.2)
国際公開日 平成26年10月16日(2014.10.16)
優先権データ
  • 特願2013-082272 (2013.4.10) JP
  • 特願2013-173696 (2013.8.23) JP
発明の名称 (英語) METHOD FOR INHIBITING PROLIFERATION OF HIGH LIX1L-EXPRESSING TUMOR CELL, AND TUMOR CELL PROLIFERATION-INHIBITING PEPTIDE
発明の概要(英語) A method for inhibiting the proliferation of high LIX1L-expressing tumor cells characterized in that the expression or function of the LIX1L gene is limited in tumor cells that are expressing LIX1L gene at a high level.
従来技術、競合技術の概要(英語) BACKGROUND ART
The current, the anti-tumor agent used for malignant tumor, anti-metabolites (Ara-C, methotrexate and the like), plant alkaloids (vincristine), alkylating agents (endoxan), anti-cancer antibiotics (adriamycin, idarubicin mitomycin and the like), such as platinum (cisplatin) formulation, there are many known. Among them, polypeptide agents include, human interferon - γ polypeptide (for example, see Patent Document 1.) Or, human tumor necrosis factor (TNF) or converts it from one part of the polypeptide (for example, see Patent Document 2.) And the like. Particularly in recent years, a high molecular target therapeutic tumor specificity (imatinib or the like), and the like (such as rituximab) monoclonal antibody was remarkable progress, has been high therapeutic effect. However, the anti-tumor agent such as imatinib, narrow spectrum anti-tumor effect, the tumor must be in selection of a drug for each addition, the problem of drug resistance. For this reason, at all times in the medical field, a wide spectrum anti-tumor effect more effective drug is demanded.
On the other hand, human LIX1L (Lix1 homolog-like, may be referred to as hLIX1L or less.) Gene, 337 amino acids in the LIX1L structural gene encoding the protein. LIX1L Has still molecular biological role is unknown, its expression amount varies depending on the cell types have been reported. Patent Document 3 is for example, LIX1L gene, activated by an agonist for the AhR CYP1A1 is directed to a compound that is sensitive to the sensitivity of the cells in a cell not, statistically significant differences in the expression (P<1.0x10-5) is present among the 266 genes were reported to be one of the 1 are. In addition, in Patent Document 4, in accordance with the allergy increases or decreases the expression levels of large numbers of genes as one group of LIX1L genes listed in the table 1.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE
  • 発明者(英語)
  • NAKAMURA Satoki
  • SUGIMURA Haruhiko
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close